Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
Arthritis & Rheumatology2019Vol. 71(12), pp. 2081–2089
Citations Over TimeTop 1% of 2019 papers
Belén Atienza‐Mateo, J. L. Martín-Varillas, V. Calvo-Río, Rosalía Demetrio‐Pablo, E. Beltrán, Juan Sánchez‐Bursón, Marina Mesquida, Alfredo Adán, M.V. Hernández, Marisa Hernández‐Garfella, Elia Valls Pascual, Lucía Martínez‐Costa, Agustí Sellas‐Fernández, Miguel Cordero‐Coma, M. Díaz-Llopis, Roberto Gallego, J.L. García-Serrano, Norberto Ortego‐Centeno, José M. Herreras, Alejandro Fonollosa, Ángel M. García-Aparicio, O. Maíz, Ana Blanco, I. Torre-Salaberri, Cruz Fernández-Espartero, Vega Jovaní, Diana Peiteado, Esperanza Pato, Juan De La Cruz, Carlos Marras, Elena Aurrecoechea, Miriam García‐Arias, Santos Castañeda, Miguel A. Caracuel‐Ruiz, Carlos Montilla, Antonio Atanes‐Sandoval, Félix Francisco, S. Insúa, Senén González-Suárez, A Sánchez-Andrade, Fernando Gamero, Luis Francisco Linares Ferrando, Fredeswinda Romero-Bueno, Alfredo J. García-González, Raquel Almodóvar, Enrique Mínguez Muro, Carmen Carrasco Cubero, Alejandro Olivé, Águeda Prior, J Vázquez, Óscar Ruiz‐Moreno, Fernando Jiménez‐Zorzo, Javier Manero, Santiago Muñoz Fernández, Cristina Fernández‐Carballido, Esteban Rubio‐Romero, Fred Antón Pages, Francisco J. Toyos‐Sáenz de Miera, M. Gandia Martinez, David Díaz‐Valle, Francisco Javier López Longo, Joan M. Nolla, Enrique Raya Álvarez, M. Revenga Martínez, J.J. González‐López, Paz Rodríguez‐Cundin, José L. Hernández, Miguel Á. González‐Gay, Ricardo Blanco
Abstract
Although both IFX and ADA are efficacious in refractory BD-related uveitis, ADA appears to be associated with better outcomes than IFX after 1 year of follow-up.
Related Papers
- → Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis(2008)377 cited
- → Effectiveness of infliximab after adalimumab failure in Crohn's disease.(2012)32 cited
- Effectiveness of infliximab after adalimumab failure in Crohn＇s disease(2012)
- → Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease(2013)17 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited